Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
20/20 BiolabsAIDX -0.23%6 Forward Dividend Yield % is 0.00% as of Aug. 03, 2026. GuruFocus rates AIDX with a GF Score™ of 6/100. The stock has 1 warning sign investors should review. Among 312 Medical Devices & Instruments companies, 20/20 Biolabs ranks worse than 320512.5% on this metric.
As of today (2026-08-03), the Forward Annual Dividend Yield of 20/20 Biolabs is 0.00%.
As of today (2026-08-03), the Trailing Annual Dividend Yield of 20/20 Biolabs is 0.00%.
AIDX's Forward Dividend Yield % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.07 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
20/20 Biolabs Forward Dividend Yield % Related Terms
AIDX vs STME, TRIB, VVOS: Forward Dividend Yield % Comparison
For the Medical Devices subindustry, 20/20 Biolabs's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
20/20 Biolabs Forward Dividend Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, 20/20 Biolabs's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where 20/20 Biolabs's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
20/20 Biolabs (AIDX) has a Forward Dividend Yield % of 0.00% as of Aug. 03, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on 20/20 Biolabs and its competitors. According to the industry distribution chart, 20/20 Biolabs ranks #999999 out of 312 companies in the Medical Devices & Instruments industry.
Is 20/20 Biolabs' Forward Dividend Yield % too high?
20/20 Biolabs' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, 20/20 Biolabs ranks #999999 out of 312 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, 20/20 Biolabs has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does 20/20 Biolabs' Forward Dividend Yield % compare to STME and TRIB?
According to the Medical Devices & Instruments industry distribution chart, 20/20 Biolabs ranks #999999 out of 312 companies for Forward Dividend Yield %. This places 20/20 Biolabs in the lower half of its industry. The industry median Forward Dividend Yield % is 2.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Devices & Instruments company?
The median Forward Dividend Yield % among Medical Devices & Instruments companies is 2.07, based on 312 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on 20/20 Biolabs and its competitors. For the Medical Devices & Instruments industry, the median Forward Dividend Yield % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 20/20 Biolabs's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 20/20 Biolabs stock overvalued right now?
20/20 Biolabs (AIDX) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. 20/20 Biolabs' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For 20/20 Biolabs (AIDX), the current Forward Dividend Yield % is 0.00% as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
6GF Score
Get the complete analysis for AIDX
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIDX has been successfully added to your 
